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ABSTRACT 
Context. The established relationship between lymph node metastasis and prognosis in 
colorectal cancer suggests that recurrence in 25% of patients with lymph nodes free of 
tumor cells by histopathology (pN0) reflects the presence of occult metastases. 
GUCY2C is a marker expressed by colorectal tumors that could reveal occult 
metastases in lymph nodes and better estimate recurrence risk. 
Objective. To examine the association of occult lymph node metastases detected by 
quantifying GUCY2C mRNA, employing the reverse transcriptase-polymerase chain 
reaction, with recurrence and survival in patients with colorectal cancer. 
Design, Setting, and Participants. Prospective enrollment of 257 patients with pN0 
colorectal cancer enrolled between March 2002 and June 2007 at 9 centers provided 
2,570 fresh lymph nodes >5 mm for histopathology and GUCY2C mRNA analysis. 
Patients were followed for a median of 24 months (range: 2-63) for disease recurrence 
or death. 
Main Outcome Measures. Time to recurrence (primary outcome) and disease-free 
survival (secondary outcome) relative to expression of GUCY2C in lymph nodes. 
Results. Thirty-two (12.5%) patients had lymph nodes negative for GUCY2C  
[pN0(mol-)], and all but two remained free of disease during follow-up (recurrence rate 
6.3% [95%CI 0.8-20.8%]). Conversely, 225 (87.5%) patients had lymph nodes positive 
for GUCY2C [pN0(mol+)], and 47 (20.9% [15.8-26.8%]) developed recurrent disease 
(p=0.006). Multivariable analyses revealed that GUCY2C in lymph nodes was an 
independent marker of prognosis. Patients who were pN0(mol+) exhibited earlier time to 
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recurrence (adjusted hazard ratio 4.66 [1.11-19.57]; p=0.035) and reduced disease-free 
survival (adjusted hazard ratio 3.27 [1.15-9.29]; p=0.026). 
Conclusion. Expression of GUCY2C in histologically negative lymph nodes appears to 
be independently associated with time to recurrence and disease-free survival in 
patients with pN0 colorectal cancer. 
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Metastasis of tumor cells to regional lymph nodes is the single most important 
prognostic factor in patients with colorectal cancer.1, 2 Recurrence rates increase from 
approximately 25% in patients with lymph nodes free of tumor cells by histopathology 
(pN0) to approximately 50% in patients with >4 lymph nodes harboring metastases.3, 4 
Adjuvant chemotherapy improves disease-free and overall survival in patients with 
histopathologically evident lymph node metastases, but its role in pN0 patients remains 
unclear.5-9 
Given the established relationship between lymph node metastasis and prognosis, 
recurrence in a substantial fraction of pN0 patients suggests the presence of occult 
metastases [pN0(mol+)3] in regional lymph nodes that escape histopathological 
detection.1, 2 Conversely, pN0 patients who are free of lymph node metastases may be 
at lowest risk for developing recurrent disease. Thus, a more accurate assessment of 
occult metastases in regional lymph nodes in pN0 patients could improve risk 
stratification in this clinically heterogeneous population. Precise evaluation of lymph 
node metastases may also identify pN0 patients who could benefit from adjuvant 
chemotherapy. 
GUCY2C (guanylyl cyclase C), an intestinal tumor suppressor, is the receptor for the 
paracrine hormones guanylin and uroguanylin, gene products frequently lost early in 
colon carcinogenesis.10, 11 Loss of hormone expression, with dysregulated GUCY2C 
signaling contributes to neoplastic transformation through unrestricted proliferation, 
crypt hypertrophy, metabolic remodeling and genomic instability.11 Selective expression 
by intestinal epithelial cells normally, and over-expression by intestinal tumor cells12-14 
reflecting receptor supersensitization in the context of ligand deprivation, suggest that 
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GUCY2C is a specific molecular marker for metastatic colorectal cancer.15-17 In a 
previous retrospective study, GUCY2C expression quantified by the reverse 
transcriptase-polymerase chain reaction (RT-PCR) was associated with disease 
recurrence.15 The current study prospectively examined the utility of GUCY2C 
quantitative (q) RT-PCR in patients with pN0 colorectal cancer to identify occult 




This study was a prospective observational trial. Investigators and clinical personnel 
were blinded to results of molecular analyses, while laboratory personnel and analysts 
were blinded to patient and clinical information. To have at least 80% power to detect a 
hazard ratio of 1.6 (P<0.05, 2-sided)18, 225 pN0 patients were required. 
PATIENTS AND TISSUES 
Between March 2002 and June 2007, we enrolled 273 stage 0-II pN0 and 87 stage III 
pN1 colorectal cancer patients who provided informed consent in writing prior to surgery 
at one of 7 academic medical centers and 2 community hospitals in the U.S. and 
Canada (Fig. 1). The study protocol was approved by the Institutional Review Board of 
each participating hospital. Patients were ineligible if they had a previous history of 
cancer, metachronous extra-intestinal cancer, or perioperative mortality associated with 
primary resection. For all eligible patients, preoperative and perioperative examinations 
revealed no evidence of metastatic disease. 
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Lymph nodes, and when available tumor specimens (51%), were dissected from colon 
and rectum resections and frozen at -80°C within one hour to minimize warm ischemia. 
Half of each resected lymph node was fixed with formalin and embedded in paraffin for 
histopathological examination. Specimens from pN0 patients were subjected to 
molecular analysis if (1) tumor samples, where available, expressed GUCY2C mRNA 
above background levels in disease-free lymph nodes (>30 copies) and (2) at least one 
lymph node was provided which yielded RNA of sufficient integrity for analysis.13 Thus, 
GUCY2C expression in tumors was below background levels in 14 patients who were 
excluded from further analysis.13 It is noteworthy that there were no differences in the 
clinicopathologic characteristics of patients with and without available tumors. Moreover, 
analysis of the 2,656 lymph nodes available from the remaining 259 pN0 patients 
revealed 86 yielding RNA of insufficient integrity by β-actin qRT-PCR, excluding two 
additional patients (see Supplemental Information).13 
Overall, the 257 pN0 patients who met eligibility criteria provided 6,699 lymph nodes 
(range 2-159, median 21 lymph nodes/patient) for histopathologic examination, of which 
2,570 nodes (range 1-33, median 8 lymph nodes/patient) were eligible for analysis by 
qRT-PCR. The greater number of lymph nodes available for histopathology compared 
to molecular analysis from pN0 patients includes those collected after formalin fixation 
or <5 mm in diameter, smaller than the limit of bisection. 
Disease status, obtained in routine follow-up by treating physicians, was provided for all 
patients through December 7, 2007. 
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RNA ISOLATION 
RNA was extracted from tissues by a modification of the acid guanidinium thiocyanate-
phenol-chloroform extraction method.15, 16 Briefly, individual tissues were pulverized in 
1.0 mL Tri-Reagent (Molecular Research Center, Cincinnati, OH) with 12-14 sterile 2.5 
mm zirconium beads in a bead mill (Biospec, Bartlesville, OK) for 1-2 min. Phase 
separation was performed with 0.1 mL bichloropropane, and the aqueous phase re-
extracted with 0.5 mL chloroform. RNA was precipitated with 50% isopropanol and 
washed with 70% ethanol. Air-dried RNA was dissolved in water, concentration 
determined by spectrophotometry, and stored at -80°C. 
RT-PCR 
GUCY2C mRNA was quantified by RT-PCR employing an established analytically 
validated assay.13 The EZ RT-PCR kit (Applied Biosystems, Foster City, CA) was 
employed to amplify GUCY2C mRNA from total RNA in a 50 µL reaction. Optical strip-
tubes were used for all reactions, which were conducted in an ABI 7000 Sequence 
Detection System (Applied Biosystems, Foster City, CA). In addition to the kit 
components [50 mM Bicine (pH 8.2), 115 mM KOAc, 10 µM EDTA, 60 nM ROX, 8% 
glycerol, 3 mM Mg(OAc)2, 300 µM each dATP, dCTP, and dGTP, 600 µM dUTP, 0.5 U 
uracil N-glycosylase, and 5 U rTth DNA polymerase], the reaction master mix contained 
900 nM each of forward (ATTCTAGTGGATCTTTTCAATGACCA) and reverse primers 
(CGTCAGAACAAGGACATTTTTCAT), 200 nM Taqman probe (FAM-TACTTGGAGG-
ACAATGTCACAGCCCCTG-TAMRA), and 1 µg RNA template. The housekeeping gene 
β-actin was amplified employing similar conditions except that forward (CCACACTGTG-
CCCATCTACG) and reverse (AGGATCTTCATGAGGTAGTCAGTCAG) primers were 
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300 nM each, while the Taqman probe (FAM-ATGCCC-X(TAMRA)-CCCCCATGCCAT-
CCTGCGTp) was 200 nM. The thermocycler program employed for RT included: 50° x 
2 min, 60° x 30 min, 95° x 5 min; and for PCR: 45 cycles of 94° x 20 sec, 62° x 1 min. 
Reactions were performed at least in duplicate and results averaged. 
STATISTICAL METHODS  
GUCY2C and β-actin mRNA were estimated by logistic regression analyses of 
amplification profiles from individual RT-PCR reactions, providing an efficiency-adjusted 
relative quantification based on parameter estimates from the fitted models which 
reduces bias and error (see Supplementary Information for details).19 The distribution of 
relative GUCY2C expression for all lymph nodes was quantified and the overall median 
computed. In the absence of established methodologies to define optimal cutpoints for 
molecular markers from variable lymph node collections from individual patients, it was 
established a priori that nodes in which relative GUCY2C mRNA was greater than or 
equal to the overall median would be considered positive while those less than the 
median would be considered negative, (see Supplementary Information for details). 
Patients were considered pN0(mol+) if 1 or more nodes were positive. 
The primary clinical endpoint was time to recurrence, measured from the date of surgery 
to the time of the last follow-up, recurrence event or death.20 Disease-free survival, 
defined as time from surgery to any event regardless of cause, was a secondary 
outcome.20 Date of recurrence was established by radiographic studies, laboratory 
studies, physical exam, and/or histopathology. Confidence intervals for raw survival 
rates were computed by the method of Clopper-Pearson.21 Survival distributions for 
patients with and without occult metastases were compared employing the likelihood 
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ratio test. While Kaplan-Meier plots display censored survival at 36 months to ensure 
availability of at least 20% of patients at all time points, analyses incorporated all events 
up to the date of last follow-up.22 The association of pN0(mol+) with categorical patient 
characteristics was quantified using chi-square tests or the Fisher’s exact test in cases 
of small sample sizes. Simultaneous prognostic effects of different parameters were 
estimated employing Cox regression analysis. Established prognostic variables in the 
Cox model for recurrence included T stage, grade, tumor location, lymphovascular 
invasion, chemotherapy, total lymph nodes harvested, and pN0 molecular status.23 The 
multivariable model for each outcome included all of the established prognostic 
measures regardless of significance in order to establish the additional independent 
prognostic effect of molecular status. A global test of proportional hazards for each of 
the Cox models was completed according to Hosmer and Lemeshow.24 All tests were 
two-sided, and p<0.05 was considered statistically significant. All analyses were 
performed with SAS v9.1 and Stata v8.0. 
RESULTS 
PATIENT CHARACTERISTICS 
The 257 pN0 patients whose lymph nodes were subjected to qRT-PCR had a mean age 
of 68 years at diagnosis and 44.8% were female (Table 1). Clinicopathologic features, 
including depth of tumor penetration (T1/2, T3, T4), and tumor anatomical location 
(right, left, sigmoid colon) were similar to national experience.3, 4, 23 Patients with colon 
cancer represented 87.4%, while those with rectal tumors were 13.6%. There were no 
statistically significant differences in baseline characteristics of patients included or 
excluded from qRT-PCR analysis, and in those with and without occult metastases, with 
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the exception of tumor grade and total lymph nodes harvested (Table 1). Patients 
exhibited the well-established direct relationships between time to recurrence, disease-
free survival and stage (Supplemental Figs. 1, 2).3, 4, 23 Adjuvant 5-fluorouracil-based 
chemotherapy, delivered at the discretion of treating physicians, was received by 22.2% 
of pN0, and 71.3% of stage III pN1, patients (Table 1). 
OCCULT METASTASES AND DISEASE RECURRENCE 
GUCY2C expression, presumably indicating the presence of occult metastases, was 
detected in at least one lymph node from 225 (87.5%) patients with pN0 colorectal 
cancer. With a median follow-up of 24.0 months (range 1.8 to 62.7) for pN0(mol+) 
patients and 35.9 months (range, 2.5 to 62.1) for pN0(mol-) patients, 20.9% (CI, 15.8-
26.8%) of patients with, but only 6.3% (CI, 0.8-20.8%) without, occult metastases 
developed recurrent disease (p=0.006; Fig. 2). Both GUCY2C-negative patients who 
developed recurrent disease provided <2 lymph nodes for analysis by qRT-PCR, 
perhaps reflecting the requirement, by any staging technique, for adequate lymph node 
sampling.3, 23, 25, 26 Subgroup analyses suggested that GUCY2C expression conferred a 
worse time to recurrence among patients with AJCC stage 0/I and II and those with 
colon and rectal cancer (Supplemental Fig. 3). Moreover, GUCY2C-positive lymph 
nodes were associated with reduced disease-free survival (Supplemental Fig. 4). Like 
time to recurrence, subgroup analyses suggested that occult metastases were 
associated with reduced disease-free survival in patients with tumors of different stages 
and locations (Supplemental Fig. 5). Time to recurrence (Fig. 2) and disease-free 
survival (Supplemental Fig. 4) in pN0(mol+) patients were comparable to that of patients 
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with stage III pN1 (stage IIIA + IIIB) disease, all of whom have histopathologically-
detectable metastases in regional lymph nodes. 
GUCY2C AS A PROGNOSTIC VARIABLE 
Univariable and multivariable analyses employing Cox proportional-hazards models 
(Figs. 3, 4) revealed that grade, tumor location, lymphovascular invasion, therapy, and 
total lymph nodes harvested contributed little as prognostic factors in this cohort of 
patients with pN0 colorectal cancer. In that context, the global test of non-proportional 
hazards for time to recurrence (chi-square, 8.67; 12 df; p=0.73) and disease-free 
survival (chi-square, 10.31; 12 df; p=0.59) indicated that there were no significant 
departures from the proportional hazards assumptions of these models. T stage was a 
weak prognostic variable, reflecting the disproportionate number of T3 (52.9%), 
compared to T4 (7.4%), tumors in the pN0 cohort and the established relationship 
between tumor size, depth of penetration and prognosis.3, 4, 9, 23. However, GUCY2C 
expression in lymph nodes provided independent prognostic information and patients 
who were pN0(mol+) exhibited earlier time to recurrence (absolute event rates: 
pN0(mol(-) 6.3%, pN0(mol+) 20.9%; adjusted hazard ratio 4.66 [1.11-19.57]; p=0.035; 
Fig. 3) and reduced disease-free survival (absolute event rates: pN0(mol(-) 12.5%, 
pN0(mol+) 26.2%; adjusted hazard ratio 3.27 [1.15-9.29]; p=0.026; Fig. 4).  
COMMENT 
A near-universal principle of cancer staging recognizes the established relationship 
between regional lymph node metastases and prognostic risk.4, 23 In colon and rectal 
cancer, lymph node metastasis is the single most important prognostic characteristic, 
representing pathologic evidence of dissemination of tumor cells beyond their primary 
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location. Clinically, approximately 50% of stage III patients will suffer disease 
recurrence.1, 2, 4, 9, 23, 25-27 Because up to 25% of patients without histological evidence of 
nodal involvement also suffer recurrent disease, it is presumed that many such patients 
harbor occult metastases not identified at the time of primary resection.1, 2 Under-
staging by conventional methods reflects the combination of insufficient numbers of 
nodes for review, the analysis of only small volumes of individual lymph node tissue 
missing metastatic tumor cells28, and the sensitivity of histopathology, which reliably 
detects only 1 cancer cell in 200 normal cells29. Molecular staging could overcome 
limitations in the detection of occult lymph node metastases by incorporating all 
available tissue into analyses, and increasing detection sensitivity through quantifiable 
disease-specific molecular markers1, 10 which nominally identify a single cancer cell in 1 
million normal cells30. 
In this study, prospective detection of occult metastases by GUCY2C qRT-PCR 
appeared to be an independent prognostic marker of risk. Molecular staging revealed 
that about 13% of pN0 patients were free of tumor cells, while about 87% had GUCY2C 
results that suggested occult metastases. Even in the context of shorter follow-up, 
which could introduce a bias against the utility of GUCY2C in this setting, pN0(mol+) 
patients exhibited a significantly greater risk of earlier disease recurrence and reduced 
disease-free survival, the primary and secondary outcomes of the study, compared to 
pN0(mol-) patients. While enrollment was sufficient to satisfy requirements for these 
outcomes, confidence intervals around estimates in multivariable analyses were broad. 
Future studies with greater numbers of patients should provide more precise estimates 
of the prognostic utility of GUCY2C qRT-PCR. 
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Although a high proportion of pN0 patients exhibit GUCY2C expression, indicating 
occult metastases, most pN0 patients will not recur.3, 23 Similarly, not all stage III 
patients who have histopathologically-detectable lymph node metastases ultimately 
develop recurrent disease.3, 23 Reconciliation of this apparent inconsistency relies on the 
recognition that nodal metastases, regardless of methods used to detect them, do not 
assure recurrence but, rather, indicate risk. In support of this concept, our study 
suggests recurrence rates for pN0(mol+) patients with occult metastases that are nearly 
identical to those for stage III pN1 patients3, the lowest stage in which all patients have 
histopathologically-detectable metastases (see Fig. 2, Supplemental Fig. 4).3, 4  
There is a well-established relationship between burden of disease, quantified as the 
number of lymph nodes harboring tumor cells by histopathology, and prognostic risk in 
colorectal cancer patients. Assuming there are adequate numbers of nodes to review 3, 
23, 25, 26
, stage III patients with >4 involved lymph nodes exhibit a recurrence rate that is 
approximately 50-100% greater than those with <3 involved nodes.3, 23 As in histology-
based analyses, one limitation of the present study is the variable number of lymph 
nodes available for molecular staging from individual patients, reflecting the requirement 
for fresh dissection of surgical specimens. Additionally, lymph nodes <5 mm were 
excluded from molecular analyses, reflecting size limits for tissue bisection, although 
they are a particularly rich source of tumor metastases.31, 32 These considerations 
suggest that the precision of staging by molecular analyses will benefit from optimum 
lymph node sampling to incorporate tumor burden into prognostic risk stratification.1, 2, 27 
An analysis of the subset of pN0 patients providing ≥12 lymph nodes for GUCY2C qRT-
PCR, applying standard AJCC definitions for pN1 and pN23, 23, revealed that those with 
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0-3 involved nodes exhibited a prognostic risk similar to pN0(mol-) patients (5.9% v 
8.3%, respectively; Supplemental Fig. 6). Conversely, those with >4 involved nodes 
exhibited a risk (<3 versus >4, p=0.027) identical to patients with stage III pN1 disease 
(Supplemental Fig. 3). Improved prognostic risk stratification by integrating detection of 
occult metastases and estimates of tumor burden underscores the essential importance 
of adequate lymph node sampling for optimum molecular1, 2, 27, as well as 
histopathological3, 23, 25, 26, staging of patients with colorectal cancer. 
Beyond the number of involved lymph nodes, there is an evolving relationship between 
the volume of cancer cells in individual nodes, disease burden, and prognostic risk.3, 28 
While metastatic foci >0.2 mm are associated with increased disease recurrence, the 
relationship between individual tumor cells or nests smaller than 0.2 mm and prognostic 
risk remains undefined.3 The emergence of qRT-PCR provides an unprecedented 
opportunity for cancer cell enumeration in tissues. However, the superior sensitivity of 
RT-PCR30, with its optimum tissue sampling and capacity for single cell discrimination, 
could identify occult cancer cells in lymph nodes below the threshold of prognostic risk3, 
limiting the specificity of molecular staging. In that context, the current study was not 
designed to identify the quantitative threshold defining risk. Indeed, one limitation of this 
study was the requirement to define a priori the diagnostic limit of GUCY2C. In future 
studies, it will be essential to more precisely define the quantitative relationship between 
marker expression and disease risk that incorporates tumor burden to optimize 
prognostic sensitivity and specificity. 
The presence of tumor cells in regional lymph nodes also directs therapy in patients 
with colon cancer. While adjuvant chemotherapy provides a survival benefit to patients 
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with stage III disease, its utility in patients with pN0 colon cancer remains uncertain, with 
marginal survival benefits in stage II patients in some, but not all, clinical trials.3, 5-9, 23, 33, 
34
 This uncertainty of treatment benefit in stage II patients is echoed in the dynamic 
evolution of treatment guidelines, in which adjuvant therapy has become discretionary in 
stage II patients with clinicopathologic features of poor prognostic risk, including T4 
stage, intestinal obstruction, and intestinal perforation.9, 33, 35, 36 It is tempting to 
speculate that heterogeneous responses to therapy in pN0 patients reflect, in part, 
heterogeneity with respect to occult nodal metastases. Moreover, standard of care 
includes adjuvant chemotherapy for stage III pN1 patients, a cohort with a recurrence 
rate identical to pN0(mol+) patients (see Fig. 2, Supplemental Fig. 4). These 
considerations highlight the importance of advancing beyond the present study to refine 
the prognostic specificity of molecular staging employing GUCY2C qRT-PCR to more 
precisely stratify risk in pN0 patients and better inform the use of adjuvant 
chemotherapy. 
Molecular staging represents one component of a comprehensive diagnostic, prognostic 
and predictive paradigm to personalize management strategies for individual patients.37, 
38
 It provides adjunctive clinicopathological information that supplements, but does not 
replace, complimentary anatomical, microscopic, and morphological staging modalities. 
Beyond enhancing these current approaches, molecular staging offers a unique 
opportunity to prioritize future complex resource-intensive analyses of primary tumors 
that will optimize patient management. In that context, analyses of primary tumors to 
define mutations, gene expression and epigenetic profiles, and proteomic signatures to 
stratify risk, predict responses to chemotherapy, and personalize interventions, may 
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best be applied to pN0(mol+), rather than pN0(mol-), patients.39-43 These considerations 
underscore the present and future importance of integrating molecular approaches 
incorporating specific markers of disease, like GUCY2C, and powerful detection 
methods like qRT-PCR, into analytical paradigms directing the management of patients 
with colorectal cancer. 
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FIGURE LEGENDS 
Figure 1. Patient selection for GUCY2C qRT-PCR Analysis. 
Figure 2. Time to Recurrence in Patients with pN0 Colorectal Cancer Stratified by 
Occult Lymph Node Metastases. Time to recurrence in 87 patients with stage III pN1 
(stage IIIA + IIIB) disease is presented for comparison. 
Figure 3. Cox Proportional-Hazards Analyses of Time to Recurrence in Patients 
with pN0 Colon Cancer Undergoing Molecular Staging. Hazard ratios (circles) with 
95% confidence intervals (horizontal lines) and P values for univariable and 
multivariable analyses describe interactions between prognostic characteristics 
(Parameter) and time to recurrence. Parameters that are significantly prognostic 
(P<0.05) are highlighted in red. 
Figure 4. Cox Proportional-Hazards Analyses of Disease-Free Survival in Patients 
with pN0 Colon Cancer Undergoing Molecular Staging. Hazard ratios (circles) with 
95% confidence intervals (horizontal lines) and P values for univariable and 
multivariable analyses describe interactions between prognostic characteristics 
(Parameter) and disease-free survival. Parameters that are significantly prognostic 
(P<0.05) are highlighted in red. 
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Table 1. Characteristics of Enrolled Patients with Colorectal Cancer. 
 pN0(mol-) pN0(mol+)  Stage III pN1 
 N % N % P N % 
Totals 32 12.5 225 87.5  87  
Age, years     0.25   
   <50 3 9.4 18 8.0  10 11.5 
   50-75 24 75.0 140 62.2  50 57.5 
   >75 5 15.6 67 29.8  27 31.0 
Sex     0.38   
   Male 20 62.5 122 54.2  43 49.4 
   Female 12 37.5 103 45.8  44 50.6 
T Stage     0.32   
   T1/T2 14 43.8 88 39.1  16 18.4 
   T3 14 43.7 122 54.2  50 57.5 
   T4 4 12.5 15 6.7  21 24.1 
Grade     0.04   
   Well 2 6.3 17 7.6  6 7.0 
   Moderate 20 62.5 178 79.1  61 70.1 
   Poor/unknown 10 31.3 30 13.3  20 22.9 
Chemotherapy     0.68   
   Yes 8 23.5 49 21.6  62 71.3 
   No 24 75.0 176 78.2  25 28.7 
Tumor Site     0.84   
   Left Colon 3 9.4 14 6.2  9 10.3 
   Right Colon 12 37.5 96 42.7  31 35.6 
   Sigmoid Colon 13 40.6 84 37.3  37 42.5 
   Rectum 4 12.5 31 13.8  10 11.5 
Nodes Harvested     0.007   
   <12 11 34.4 34 15.1  20 23.0 
   >12 21 65.6 191 84.9  67 77.0 
 
